Status:
ACTIVE_NOT_RECRUITING
Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease
Lead Sponsor:
House Ear Institute
Collaborating Sponsors:
Cures Within Reach
Conditions:
Meniere Disease
Allergic Rhinitis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate a previously FDA-approved medication that is known to help with allergy symptoms to see if it can decrease symptoms in patients with Meniere's Disease.
Eligibility Criteria
Inclusion
- Adults 18 years of age or older
- Must meet all AAO-HNS 2020 criteria for definite or probable Meniere's Disease
- Must have a skin test positive for allergy
- Is already a candidate for treatment with montelukast for allergic rhinitis/failed first line over-the-counter allergy treatments
Exclusion
- Had a previous surgical procedure for treatment of vertigo
- Currently receiving any allergy immunotherapy or taking montelukast or a beta-blocker
- Pregnant or recent pregnancy ((≤ 8 weeks postpartum), or lactation)
- Current hospitalization for any reason
- Any active, acute, or chronic pulmonary disorder other than asthma
- History of intubation for asthma
Key Trial Info
Start Date :
June 7 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2025
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT04815187
Start Date
June 7 2021
End Date
December 31 2025
Last Update
March 18 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
House Ear Clinic
Los Angeles, California, United States, 90057
2
House Institute Foundation
Los Angeles, California, United States, 90057